Efficacy of a Bioresorbable Matrix in Healing Complex Chronic Wounds: An Open-Label Prospective Pilot Study

被引:0
|
作者
Manning, Sarah W. [1 ]
Humphrey, David A. [1 ]
Shillinglaw, William R. [1 ]
Crawford, Eric [2 ]
Pranami, Gaurav [2 ]
Agarwal, Ankit [2 ]
Schurr, Michael J. [1 ]
机构
[1] Univ North Carolina Hlth Sci, Mt Area Hlth Educ Ctr, Dept Surg, Asheville, NC USA
[2] Imbed Biosci Inc, Madison, WI 53719 USA
基金
美国国家卫生研究院;
关键词
bioresorbable; antimicrobial; silver; matrix; chronic; wound; infection; SILVER DRESSINGS; CYTOTOXICITY; MANAGEMENT; SYMPTOMS; TISSUE; CELL;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Objective. The goal of this prospective clinical study was to assess the effectiveness of a novel bioresorbable polymeric matrix impregnated with ionic and metallic silver as a primary wound contact dressing in healing stagnant or deteriorating chronic wounds. Materials and Methods. Thirty-two patients with a total of 35 chronic wounds undergoing treatment at the Wound Healing and Hyperbaric Center at Mission Hospital were recruited under a protocol approved by the institutional review board. The wounds included venous stasis ulcers, diabetic foot ulcers, postoperative surgical wounds, burn wounds, and chronic, nonpressure lower extremity ulcers. At baseline, all wounds were nonhealing (ie, stagnant or deteriorating) for a median of 39 weeks (range, 3-137 weeks) and suspected of persistent microbial colonization that had not responded to traditional antimicrobial products and/or antibiotics. The aforementioned matrix was applied to wounds once every 3 days and covered with a secondary dressing. Previously prescribed protocols of care, such as debridement or compression wraps, were continued, but prior antimicrobial dressings or antibiotics were replaced with the matrix. Wound assessments at 3 weeks and 12 weeks post intervention are reported. Results. Three patients were excluded due to patients lost to follow-up after initial application. At 3 weeks, 72% of wounds (22/32) had significantly improved healing with an average wound area reduction of 66%. By 12 weeks, 91% of wounds (29/32) either healed completely (ie, fully reepithelialized) or improved significantly with an average wound area reduction of 73%. The matrix was well tolerated; no patient reported discomfort with the application of the matrix. Conclusions. The micrometer-thick bioresorbable matrix presents a new form factor to wound management, conforming intimately to the underlying wound bed to exert localized and sustained antimicrobial action of noncytotoxic levels of silver. The application of the matrix on the wound surface in protocols of care was safe and well tolerated, and it facilitated improvements in healing of a majority of the stagnant or deteriorating complex chronic wounds.
引用
收藏
页码:309 / 318
页数:10
相关论文
共 50 条
  • [41] Open-Label Pilot Study of Modafinil for Methamphetamine Dependence
    McGaugh, Janette
    Mancino, Michael J.
    Feldman, Zachary
    Chopra, Mohit P.
    Gentry, W. Brooks
    Cargile, Christopher
    Oliveto, Alison
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (05) : 488 - 491
  • [42] Topiramate in the treatment of trichotillomania: an open-label pilot study
    Lochner, Christine
    Seedat, Soraya
    Niehaus, Dana J. H.
    Stein, Dan J.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (05) : 255 - 259
  • [43] Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study
    Agarwala, S
    Jain, D
    Joshi, VR
    Sule, A
    RHEUMATOLOGY, 2005, 44 (03) : 352 - 359
  • [44] Efficacy of Azithromycin for Treatment of Acute Exacerbation of Chronic Fibrosing Interstitial Pneumonia: A Prospective, Open-Label Study with Historical Controls
    Kawamura, Kodai
    Ichikado, Kazuya
    Suga, Moritaka
    Yoshioka, Masakazu
    RESPIRATION, 2014, 87 (06) : 478 - 484
  • [45] Effects of Embodiment in Virtual Reality for Treatment of Chronic Pain: Pilot Open-Label Study
    Saby, Adam
    Alvarez, Anthony
    Smolins, David
    Petros, James
    Nguyen, Lincoln
    Trujillo, Michael
    Aygun, Oytun
    JMIR FORMATIVE RESEARCH, 2024, 8
  • [46] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Adem T. Can
    Daniel F. Hermens
    Megan Dutton
    Cyrana C. Gallay
    Emma Jensen
    Monique Jones
    Jennifer Scherman
    Denise A. Beaudequin
    Cian Yang
    Paul E. Schwenn
    Jim Lagopoulos
    Translational Psychiatry, 11
  • [47] Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
    Can, Adem T.
    Hermens, Daniel F.
    Dutton, Megan
    Gallay, Cyrana C.
    Jensen, Emma
    Jones, Monique
    Scherman, Jennifer
    Beaudequin, Denise A.
    Yang, Cian
    Schwenn, Paul E.
    Lagopoulos, Jim
    TRANSLATIONAL PSYCHIATRY, 2021, 11 (01)
  • [48] Efficacy and Tolerability of Pregabalin Versus Topiramate in the Prophylaxis of Chronic Daily Headache With Analgesic Overuse: An Open-Label Prospective Study
    Rizzato, Barbara
    Leone, Giorgia
    Misaggi, Giulia
    Zivi, Ilaria
    Diomedi, Marina
    CLINICAL NEUROPHARMACOLOGY, 2011, 34 (02) : 74 - 78
  • [49] Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
    Yoon, Ho-Kyoung
    Kim, Yong-Ku
    Han, Changsu
    Ko, Young-Hoon
    Lee, Heon-Jeong
    Kwon, Do-Young
    Kim, Leen
    ACTA NEUROPSYCHIATRICA, 2011, 23 (04): : 179 - 183
  • [50] Rituximab for refractory polymyositis: An open-label prospective study
    Mok, Chi Chiu
    Ho, Ling Yin
    To, Chi Hung
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (09) : 1864 - 1868